Skip to main content
NewslettersWatchlist

Anixa Biosciences Inc(ANIX-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low2.89
Day High3.01
Open:2.89
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
PR Newswire
Anixa Biosciences Completes Treatment of First Patient Cohort in Ovarian Cancer CAR-T Clinical Trial
PR Newswire
Anixa Biosciences Announces Issuance of Additional U.S. Patent for Ovarian Cancer Vaccine Technology
PR Newswire
Anixa Biosciences Establishes Cancer Business Advisory Board
Baystreet
Jobs Numbers Roll out in Canada During Shortened Week
PR Newswire
Anixa Biosciences to Participate in September Investor Conferences
PR Newswire
Anixa Biosciences Announces Treatment of Third Patient in Ovarian Cancer CAR-T Clinical Trial
PR Newswire
Anixa Biosciences Announces Invited Presentation on Ovarian Cancer CAR-T Therapy at the 8th Annual CAR-TCR Summit
ACCESSWIRE
Could Anixa Biosciences (NASDAQ:ANIX) Be Developing The Vaccine To End One Of The Deadliest Types Of Breast Cancer?
PR Newswire
Anixa Biosciences Announces Opening of Enrollment for Keytrudaยฎ Arm in Ongoing Breast Cancer Vaccine Clinical Trial
PR Newswire
Anixa Biosciences Announces Notice of Allowance of Additional Patent on Ovarian Cancer Vaccine Technology
PR Newswire
Anixa Biosciences Announces Treatment of Second Patient in its Ovarian Cancer CAR-T Clinical Trial
PR Newswire
Anixa Biosciences Clarifies Poster Presentation on Company Website
PR Newswire
Anixa Biosciences and Cleveland Clinic Present Positive Data for Phase 1 Study of Breast Cancer Vaccine
PR Newswire
Anixa Biosciences Announces Presentation on Breast Cancer Vaccine Trial at the 2023 AACR Annual Meeting
PR Newswire
Anixa Biosciences Reassures Shareholders It Has No Accounts at Silicon Valley Bank
PR Newswire
Anixa Biosciences Announces Notice of Allowance of Additional Key Patent on Breast Cancer Vaccine Technology
PR Newswire
Anixa Biosciences to Present at Biotech Showcase 2023
PR Newswire
Anixa Biosciences Announces Presentation on Breast Cancer Vaccine Trial at the 2022 San Antonio Breast Cancer Symposium
PR Newswire
Dr. Jose Conejo-Garcia, Invited to Present Keynote Address at Duke Cancer Institute, will Discuss Anixa Biosciences' Ovarian Cancer CAR-T Therapy
PR Newswire
Anixa Biosciences Announces Presentation on Ovarian Cancer CAR-T Therapy Trial at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
PR Newswire
Anixa Biosciences' Ovarian Cancer CAR-T Therapy to be Presented at the Rivkin Center & American Association of Cancer Research (AACR) 14th Biennial Ovarian Cancer Research Symposium
PR Newswire
Anixa Biosciences to Present at the H.C. Wainwright 24th Annual Global Investment Conference
PR Newswire
Anixa Biosciences Announces Treatment of First Patient in its Ovarian Cancer CAR-T Clinical Trial

Profile

Anixa Biosciences, Inc. operates as a bio-technology company. It develops diagnostics and therapeutics to detect cancer. Anixa Biosciences Inc., formerly known as ITUS Corporation, is based in San Jose, United States.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright ยฉ 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright ยฉ 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.